Promyelocytic leukemia (PML) nuclear bodies (PML NBs) are discrete subnuclear domains organized by the promyelocytic leukemia protein PML, a tumor suppressor essential for multiple apoptotic pathways. We have recently described a novel family of cellular factors, the THAP proteins, characterized by the presence at their amino-terminus of an evolutionary conserved putative DNA-binding motif, designated THAP domain. Here, we report that THAP1 is a novel nuclear proapoptotic factor associated with PML NBs, which potentiates both serum withdrawal-and TNFa-induced apoptosis, and interacts with prostate-apoptosis-response-4 (Par-4), a well characterized proapoptotic factor, previously linked to prostate cancer and neurodegenerative diseases. We show that endogenous Par-4 colocalizes with ectopic THAP1 within PML NBs in primary endothelial cells and fibroblasts. In addition, we found that Par-4 is a component of PML NBs in blood vessels, a major site of PML expression in vivo. Finally, we investigated the role of the THAP domain in THAP1 activities and found that this putative DNA-binding domain is not required for Par-4 binding and localization within PML NBs, but is essential for THAP1 proapoptotic activity. Together, our results provide an unexpected link between a nuclear factor of the THAP family, the proapoptotic protein Par-4 and PML nuclear bodies.
Introduction
Promyelocytic leukemia (PML) nuclear bodies (PML NBs), also known as PODs (PML oncogenic domains), ND10 (nuclear domain 10) and Kr bodies, are discrete subnuclear domains that are specifically disrupted in cells from acute promyelocytic leukemia (APL), a distinct subtype of human myeloid leukemia (Ruggero et al., 2000; Zhong et al., 2000b; Negorev and Maul, 2001 ). Their name derives from their most intensively studied protein component, the PML protein, a RING finger IFN-inducible protein encoded by a gene originally cloned as the t(15; 17) chromosomal translocation partner of the retinoic acid receptor a (RARa) locus in APL (de The et al., 1991) . The analysis of mice, where the pml gene was disrupted by homologous recombination, has revealed that PML functions as a tumor suppressor in vivo (Wang et al., 1998a) , which is essential for multiple apoptotic pathways (Wang et al., 1998b) . PML À/À mice and cells are protected from Fas, tumor necrosis factor (TNFa), ceramide and IFN-induced apoptosis as well as from DNA-damage-induced apoptosis. However, the molecular mechanisms through which PML modulates the response to proapoptotic stimuli are not well understood (Quignon et al., 1998; Wang et al., 1998b) . Recent studies indicate that PML may act by recruiting into PML NBs, proapoptotic proteins such as p53 and Daxx (Ishov et al., 1999; Torii et al., 1999; Ferbeyre et al., 2000; Fogal et al., 2000; Guo et al., 2000; Li et al., 2000; Pearson et al., 2000; Zhong et al., 2000c; Hofmann et al., 2001; D'Orazi et al., 2002) . p53-Dependent DNA-damage induced apoptosis, transcriptional activation by p53 and induction of p53 target genes are all impaired in PML À/À primary cells (Guo et al., 2000; Pearson et al., 2000) . PML physically interacts with p53 and acts as a transcriptional coactivator for p53 (Fogal et al., 2000; Guo et al., 2000) . This coactivatory role of PML is absolutely dependent on its ability to recruit p53 in the PML NBs (Fogal et al., 2000; Guo et al., 2000) . PML may act by stimulating post-translational modifications of p53, since PML-mediated recruitment of p53 and the CBP acetyltransferase or the homeodomain-interacting protein kinase-2 within PML NBs has been shown to induce formation of trimeric p53-PML-CBP or p53-PML-HIPK2 complexes, resulting in the stimulation of p53 acetylation or phosphorylation, and increased p53 transcriptional activity (Guo et al., 2000; Pearson et al., 2000; Hofmann et al., 2001; D'Orazi et al., 2002) . Daxx could be another important mediator of PML proapoptotic activities (Ishov et al., 1999; Torii et al., 1999; Li et al., 2000; Zhong et al., 2000c) . Daxx was initially identified by its ability to enhance Fas-induced cell death (Yang et al., 1997) . Daxx interacts with PML and accumulates in the PML NBs (Ishov et al., 1999; Torii et al., 1999; Li et al., 2000; Zhong et al., 2000c) . Inactivation of PML results in delocalization of Daxx from PML NBs and complete abrogation of Daxx proapoptotic activity (Zhong et al., 2000c) . PML NBs contain several other proteins in addition to Daxx and p53, including the autoantigen Sp100 (Sternsdorf et al., 1999) , the transcriptional coactivator CBP (LaMorte et al., 1998) , the Bloom syndrome DNA helicase BLM (Zhong et al., 1999) and the small ubiquitin-like modifier SUMO-1 (Ishov et al., 1999; Zhong et al., 2000a) , but they are not known to be involved in apoptosis.
We have recently described a novel family of cellular factors, the THAP proteins, characterized by the presence of an evolutionary conserved protein motif at their amino-terminus (Roussigne et al., 2003) . This motif, designated THAP domain, exhibits striking similarities with the DNA-binding domain of Drosophila melanogaster P-element transposase, suggesting that the THAP proteins may correspond to a novel family of cellular DNA-binding proteins. In humans, the THAP family comprises at least 12 distinct members, including the death-associated protein DAP4/p52rIPK (Deiss et al., 1995; Gale et al., 1998) as well as 11 novel human proteins (THAP1 to THAP11) (Roussigne et al., 2003) .
In this paper, we show that THAP1 is a novel nuclear proapoptotic factor associated with PML NBs, which interacts with the proapoptotic protein Par-4 and potentiates both serum withdrawal-and TNFa-induced apoptosis. Par-4 is a 38 kDa protein, initially identified as the product of a gene specifically upregulated in prostate tumor cells undergoing apoptosis (Sells et al., 1994) , which has been shown to function as a transcriptional regulator with corepressor (Johnstone et al., 1996) or coactivator (Richard et al., 2001) properties for distinct isoforms of transcription factor WT1, the Wilms' tumor suppressor protein. Consistent with an important role of Par-4 in apoptosis, ectopic expression of Par-4 in NIH-3T3 cells (Diaz-Meco et al., 1996 , neurons (Guo et al., 1998) , prostate cancer and melanoma cells (Sells et al., 1997) has been found to sensitize these cells to apoptotic stimuli. In addition, downregulation of Par-4 is critical for ras-induced survival and tumor progression (Barradas et al., 1999) and suppression of Par-4 production by antisense technology prevents apoptosis in several systems (Sells et al., 1997) , including different models of neurodegenerative disorders (Guo et al., 1998; Mattson et al., 1999) , further emphasizing the critical role of Par-4 in apoptosis. At the carboxy terminus, Par-4 contains both a leucine zipper domain (aa 290-332), and a partially overlapping death domain (aa 258-332), deletion of which abrogates Par-4 proapoptotic function (Diaz-Meco et al., 1996; Sells et al., 1997; Guo et al., 1998) . The Par-4 death domain (Par-4DD) mediates Par-4 interaction with the three known Par-4-binding partners: WT1 (Johnstone et al., 1996) , protein kinase C atypical isoforms (aPKCs) (Diaz-Meco et al., 1996) and DAP-like kinase Dlk/ZIP (Page et al., 1999) . Here, we show that Par-4DD also mediates Par-4 interaction with THAP1 both in vitro and in vivo. Full-length endogenous Par-4 colocalizes with THAP1 within PML NBs in primary endothelial cells or fibroblasts. Par-4 is also found to accumulate into PML NBs in blood vessel endothelial cells, a major site of PML expression in vivo (Flenghi et al., 1995; Terris et al., 1995) . Altogether, our results provide an unexpected link between a nuclear factor of the THAP family, the proapoptotic protein Par-4 and PML nuclear bodies.
Results

THAP1 is a novel nuclear protein associated with PML NBs
In the past few years, we have focused on the molecular characterization of novel genes expressed in the endothelial cells of postcapillary high endothelial venules (HEV), specialized blood vessels involved in lymphocyte migration (Girard and Springer, 1995b; Girard et al., 1999) . We isolated the THAP1 cDNA fortuitously in a two-hybrid screen of an HEV endothelial cell cDNA library with a cytokine bait. It encodes a novel human protein of 213 amino acids that exhibits 93% identity with its mouse orthologue ( Figure 1a ). The only
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To analyse the subcellular localization of the THAP1 protein, a GFP-THAP1 expression construct was transfected into primary human endothelial cells. Analysis by fluorescence microscopy revealed that the GFP-THAP1 fusion protein localizes exclusively in the nucleus with both a diffuse distribution and an accumulation into nuclear dots in the majority of transfected cells (Figure 1c, d ). We used indirect immunofluorescence microscopy to examine a possible colocalization of the nuclear dots containing GFP-THAP1 with known nuclear domains (replication factories, coiled bodies, nuclear bodies). This analysis revealed that GFP-THAP1 staining exhibits a complete overlap with the staining pattern obtained with antibodies directed against PML (Figure 1c) or Daxx, another well-characterized component of PML NBs (Figure 1d ). Together, these results reveal that THAP1 is a novel nuclear protein associated with PML NBs.
THAP1 interacts with the proapoptotic protein Par-4
To identify cellular targets of THAP1, we performed a yeast two-hybrid screen of a human endothelial cell cDNA library using THAP1 as a bait. From 15 Â 10 6 yeast transformants, we identified three positive clones that exhibited a robust growth on selective media lacking histidine and adenine. Sequencing of these clones revealed three identical library plasmids that corresponded to a partial cDNA coding for the last 147 amino acids (positions 193-342) of the proapoptotic protein Par-4. Interaction of THAP1 with Par-4 was confirmed using full-length Par-4 (Figure 2a ). We then examined whether the death domain at the C-terminus of Par-4 (Par-4DD), previously shown to be involved in Par-4 binding to WT-1 and aPKC, was required for the interaction between THAP1 and Par-4. We found that deletion of this domain (Par-4D) abrogates THAP1/Par-4 interaction. In contrast, positive interaction between THAP1 and Par-4DD was observed, indicating that the Par-4DD is not only required but also sufficient for the interaction with THAP1 ( Figure 2a ). Similar results were obtained when two-hybrid experiments were performed in the opposite orientation using Par-4 or Par-4 mutants (Par-4D and Par-4DD) as baits instead of THAP1 ( Figure 2a ). To confirm the interaction observed in yeast, we performed in vitro GST pull-down assays. Par-4DD, expressed as a GST-tagged fusion protein and immobilized on glutathione sepharose, was incubated with radiolabelled in vitro translated THAP1. As expected, THAP1 interacted with GST/Par-4DD but not with GST (Figure 2b , c).
We next addressed whether THAP1 is able to associate with Par-4DD in vivo. For this purpose, we Figure 3b ). The effect of GFP-THAP1 on myc-Par-4DD redistribution was specific since it was not observed with GFP-APS kinase-1 (APSK1), a nuclear enzyme unrelated to THAP1 ( Figure 3c ) (Besset et al., 2000) , nor with GFP-SUMO-1, another component of PML NBs ( Figure 3d ). These later results suggest specific recruitment of myc-Par-4DD within PML NBs by GFP-THAP1 and strongly support interaction of the two proteins in vivo. Altogether, these data provide both in vitro and in vivo evidence for a direct interaction of THAP1 with the proapoptotic protein Par-4, mediated through the Par-4 death domain.
Par-4 is a component of PML NBs in primary human endothelial cells and fibroblasts
The localization of THAP1 within PML NBs and its interaction with Par-4 led us to investigate a possible association of endogenous Par-4 with PML NBs. Confocal immunofluorescence microscopy using affinity-purified anti-Par-4 antibodies (Sells et al., 1997; Guo et al., 1998) was performed on primary human endothelial cells (Figure 4a , c) or fibroblasts (Figure 4b , d) fixed with methanol/acetone, which makes PML NBs components accessible for antibodies (Sternsdorf et al., 1997) . This analysis showed an association of Par-4 immunoreactivity with nuclear dot-like structures, in addition to diffuse nucleoplasmic and cytoplasmic staining (Figure 4a To further confirm the localization of endogenous Par-4 within PML NBs, a possible association of Par-4 with PML NBs in normal tissue in vivo was analysed by immunostaining of cryosections from human tonsils ( Figure 5 ). It has previously been shown that, on frozen sections, anti-PML antibodies detect the presence of one to three individual dots in the nuclei of endothelial cells from blood vessels, a preferential site of PML expression in vivo (Flenghi et al., 1995; Terris et al., 1995) . We observed a similar dot-like staining pattern with antiPar-4 antibodies in endothelial cells from HEV blood vessels (Figure 5a ). Double labelling with anti-PML antibodies revealed overlapping Par-4 and PML staining patterns (Figure 5b ) indicating that Par-4 is a component of PML NBs in vivo in HEV blood vessel endothelial cells.
PML recruits THAP1 and Par-4 to PML NBs in immortalized Hela cells
Since it has been shown that PML plays a critical role in the assembly of PML NBs by recruiting other components (Ishov et al.,. 1999; Zhong et al., 2000a; Lallemand-Breitenbach et al., 2001) , we next wanted to determine whether PML is involved in the recruitment of THAP1 and Par-4 to PML NBs. For this purpose, we made use of the observation that both endogenous Par-4 and ectopic GFP-THAP1 do not accumulate in PML NBs in human Hela cells or mouse 3T3 fibroblasts. Expression vectors for GFP-THAP1 and HA-PML or HA-SP100 were cotransfected into Hela cells and the localization of endogenous Par-4, GFP-THAP1 and HA-PML or HA-SP100, was analysed by triple staining confocal microscopy. In Hela cells transfected with HA-PML (Figure 6a ), endogenous Par-4 and GFP-THAP1 were recruited to PML NBs, whereas in cells transfected with HA-SP100 (Figure 6b ), both Par-4 and GFP-THAP1 exhibited diffuse staining without accumulation in PML NBs. These findings indicate that recruitment of THAP1 and Par-4 to PML NBs depends on PML but not on SP100.
THAP1 is a novel proapoptotic factor
Since PML and PML NBs have been linked to regulation of cell death and Par-4 is a well-established proapoptotic factor, we examined whether THAP1 can modulate cell survival. To this end, we used mouse 3T3 fibroblasts, which have previously been used to analyse the proapoptotic activity of Par-4 (Diaz-Meco et al., 1996; Berra et al., 1997) , and can be easily transfected. We first analysed serum withdrawal-induced apoptosis in cells transiently transfected with expression vectors for GFP-THAP1, GFP-Par-4 or, as control, GFP-APSK1, a nuclear enzyme unrelated to THAP1 and apoptosis (Besset et al., 2000) . Transfected cells were deprived of serum for 24 h and apoptosis was analysed by in situ TUNEL assay (Figure 7a , b) or DAPI staining (Figure 7c ). TUNEL assays revealed that overexpression of GFP-THAP1, but not of control GFP-APSK1, significantly increases vulnerability to apoptosis following serum withdrawal (Figure 7a, b) . Analysis of nuclear condensation upon DAPI staining gave similar results (Figure 7c) . At 24 h after serum withdrawal, apoptosis was found in 10-20% of untransfected 3T3 cells and in 3T3 cells overexpressing GFP-APSK1. Levels of serum withdrawal induced apoptosis were significantly increased to about 65-70% in cells overexpressing GFPPar-4 or GFP-THAP1. These results demonstrate that THAP1, similarly to Par-4, does promote apoptosis in 3T3 cells after serum withdrawal. Since Par-4 has previously been shown to potentiate (TNFa)-induced apoptosis and PML is essential for apoptosis induction by TNFa Wang et al., 1998b) , we next examined the effects of GFP-THAP1 overexpression on TNFa-induced apoptosis. The 3T3 cells transiently transfected with expression vectors for GFP-THAP1 or, as control, GFP-APSK1, were treated with TNFa in the presence of serum, and apoptosis was scored 24 h later by DAPI staining. We found that overexpression of GFP-THAP1 enhances TNFa-induced apoptosis (Figure 7d ). This effect was specific since it was not observed in cells overexpressing GFP-APSK1 (Figure 7d ). We concluded from these experiments that THAP1 is a proapoptotic polypeptide that potentiates both serum-withdrawal and TNFa-induced apoptosis.
The THAP domain is essential for THAP1 proapoptotic activity
To study the possible role of the amino-terminal THAP domain in THAP1 proapoptotic activity and binding to Par-4, we used a THAP1 mutant, THAP1-C1, that is deleted of the THAP domain (Figure 8a ). Confocal immunofluorescence microscopy revealed that this THAP1 deletion mutant (GFP-THAP1-C1) colocalizes with PML in PML NBs (Figure 8b ), indicating that the THAP domain is not required for THAP1 localization within PML NBs. We then performed in vitro GST pull-down assays to examine the role of the THAP domain in Par-4 binding. We found that THAP1-C1 interacts with GST/Par-4DD (Figure 8c) , indicating that the THAP domain is not required for THAP1/Par-4 interaction. To analyse the role of the THAP domain in THAP1 proapoptotic activity, we performed cell death assays in mouse 3T3 cells transiently transfected with GFP-THAP1-C1 or, as controls, GFP-APSK1 and GFP-THAP1 fusion proteins expression vectors. Levels of serum withdrawal induced apoptosis were significantly increased from 18% in cells overexpressing GFP-APSK1 (negative control) to about 65% in cells overexpressing wild-type GFP-THAP1 (positive control). Deletion of the THAP domain abrogated most of this effect since serumwithdrawal-induced apoptosis was reduced to 28% in cells overexpressing GFP-THAP1-C1 (Figure 8d ). These results indicate that the THAP domain, although not required for Par-4 binding and localization to PML NBs, is essential for THAP1 proapoptotic activity.
Discussion
Although PML has emerged as a critical mediator of multiple apoptotic pathways (Wang et al., 1998b) , the molecular mechanisms by which it exerts these effects remain largely unknown (Ruggero et al., 2000) . It has been proposed that PML could exert its proapoptotic functions by actively recruiting to PML NBs, proapoptotic factors such as p53 and Daxx (Guo et al., 2000; Zhong et al., 2000c) . Here, we report that the PML NBsassociated factor THAP1 is a novel nuclear proapoptotic factor, which contains a putative DNA-binding domain (THAP domain) essential for its proapoptotic activity. We show that THAP1 interacts and colocalizes within PML NBs with Par-4. Par-4 is a well-characterized proapoptotic factor, which is upregulated in cells undergoing apoptotic cell death and that seems to play a key role in prostate cancer and neurodegenerative diseases (Sells et al., 1994 (Sells et al., , 1997 Guo et al., 1998; Mattson et al., 1999) . Cell fractionation experiments have previously revealed that Par-4 is found in both the cytoplasm and the nucleus (Johnstone et al., 1996) , and both nuclear and cytoplasmic roles of Par-4 have been proposed (Diaz-Meco et al., 1996; Johnstone et al., 1996; Richard et al., 2001) . However, association of Par-4 with PML NBs was not reported. Interestingly, another Par-4-binding partner, the DAP-like kinase Dlk/ZIP (Page et al., 1999) , has also been found associated with PML NBs suggesting that Par-4 may associate within PML NBs with distinct protein partners, including THAP1 and Dlk/ Similarly to p53 and Daxx, THAP1 and Par-4 may function in transcription regulation. Par-4 has previously been shown to function as a transcriptional regulator that exhibits corepressor (Johnstone et al., 1996) or coactivator activities (Richard et al., 2001 ) for distinct isoforms of transcription factor WT1. The presence of the THAP domain in THAP1, a putative DNA-binding motif homologous to the DNA-binding domain of Drosophila P-element transposase (Lee et al., 1998) supports the possibility that THAP1 is a DNAbinding transcription factor. As suggested for WT1, THAP1 may therefore recruit Par-4 to specific promoters to either stimulate or inhibit transcriptional activation of genes involved in apoptosis, such as the antiapoptotic gene Bcl2, which is known to be downregulated by Par-4 (Qiu et al., 1999) .
Localization of THAP1 and Par4 to PML NBs is unlikely to be absolutely essential for their proapoptotic activity since we found that both proteins exhibit significant proapoptotic activities in mouse 3T3 fibroblasts, where they are not associated with PML NBs. PML and PML NBs may rather play a regulatory role by modulating functions of Par-4 and THAP1 in apoptosis and/or transcriptional control with several distinct mechanisms. First, PML NBs could represent centers where Par-4 and THAP1 are assembled into multiprotein complexes and/or post-translationally modified, as it has been shown for p53 (Guo et al., , 2002) . Alternatively, the PML NBs could represent nuclear degradation sites or nuclear storage depots (Negorev and Maul, 2001) , which sequester and thereby inactivate Par-4 and THAP1 by titrating them from the active pool in the nucleoplasm. This has been shown for Daxx (Li et al., 2000; Lehembre et al., 2001) . Daxx functions as a transcriptional repressor, which interacts with transcriptional regulators such as Pax3 and Ets1, and inhibits gene activation. PML can regulate the repressor activity of Daxx by sequestrating it into the PML NBs (Li et al., 2000; Lehembre et al., 2001) , thus allowing derepression of Daxx target genes. Whatever the effect of PML NBs localization, a role of THAP1 and Par-4 in transcriptional control would be consistent with the observation that PML NBs contain many transcription factors and appear to play a key role in the regulation of transcription (Zhong et al., 2000b) . We found that the THAP domain of human THAP1, which is not required for Par-4 binding and localization to PML NBs, is essential for THAP1 proapoptotic activity. This domain defines a novel evolutionary conserved gene family with at least 12 distinct members in the human genome (Roussigne et al., 2003) . Although the THAP proteins are likely to be involved in diverse cellular processes, some of them could potentially function in apoptosis, similarly to THAP1. These later may include THAP4, which in GenBank (Accession No. AF258556) carried the intriguing annotation of 'Novel cDNA clones with functions in inhibiting cancer cell growth', and death-associated protein DAP4/p52rIPK which was previously identified in a genetic screen for genes involved in IFNg-induced apoptosis in Hela cells (Deiss et al., 1995) and in a twohybrid screen for indirect activators of the interferon-induced kinase PKR, an important mediator of stress-induced apoptosis (Gale et al., 1998) . In any case, future studies will be required to determine whether other THAP proteins, in addition to THAP1, play a role in apoptosis.
Materials and methods
Two-hybrid cDNA library construction and screening
For the yeast two-hybrid screening, a cDNA library was generated from microvascular human high endothelial venules endothelial cells (HEVEC). HEVEC were purified from human tonsils by immunomagnetic selection with monoclonal antibody MECA-79 as previously described (Girard and Springer, 1995a) . The SMART PCR cDNA library Construction Kit (Clontech, Palo Alto, CA, USA) was first used to generate fulllength cDNAs from 1 mg HEVEC total RNA. Oligo-dTprimed HEVEC cDNA was then digested with SfiI and directionally cloned into pGAD424-Sfi, a two-hybrid vector generated by inserting a SfiI linker (5 0 -GAATTCGGCCAT-TATGGCCTGCAGGATCCGGCCGCCTCGGCCCAGGA-TCC-3 0 ) between EcoRI and BamHI cloning sites of pGAD424 (Clontech). The resulting pGAD424-HEVEC cDNA twohybrid library (mean insert size >1 kb, B3 Â 10 6 independant clones) was amplified in E. coli. Screening of the two-hybrid HEVEC cDNA library was performed in yeast strain AH109 (Clontech) using as a bait the human THAP1 full-length cDNA inserted into the MATCHMAKER two-hybrid system 3 vector pGBKT7 (Clontech). Plasmid DNA was extracted from positive colonies and used to verify the specificity of the interaction by cotransformation in AH109 with pGBKT7THAP1 or control baits pGBKT7, pGBKT7-lamin and pGBKT7-hevin. Positive interaction between THAP1 and Par-4 was confirmed using full-length Par-4 bait (pGBKT-Par-4) and prey (pGADT7-Par-4).
Mammalian cell culture and transfection
Human primary endothelial cells from umbilical vein (HU-VEC, kindly provided by Dr A Bouloumie´, Toulouse, France) were grown in complete ECGM medium (PromoCell, Heidelberg, Germany), plated on coverslips and transiently transfected in RPMI medium using GeneJammer transfection reagent according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA). Human primary skin fibroblasts (kindly provided by Dr P Sassone-Corsi, Strasbourg, France) were grown in modified Eagle's medium (MEM) supplemented with 20% fetal calf serum and FGF-2 (all from Life Technologies, Grand Island, NY, USA), plated on coverslips and transiently transfected using GeneJammer transfection reagent (Stratagene). Human Hela cells and mouse 3T3-TO fibroblasts (Clontech) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin (all from Life Technologies, Grand Island, NY, USA), plated on coverslips, and transiently transfected with Lipofectamine reagent (Life Technologies) according to the supplier's instructions or with calcium phosphate method using 2 mg plasmid DNA.
Plasmid constructions
The full-length coding region of THAP1 (GenBank # BC021721) was amplified by PCR from HEVEC cDNA with primers 2HMR10 (5 0 -CCGAATTCAGGATGGTGCAGTC CTGCTCCGCCT-3 0 ) and 2HMR9 (5 0 -CGCGGATCCTGCT GGTACTTCAACTATTTCAAAGTAGTC-3 0 ), digested with EcoRI and BamHI, and cloned in frame downstream of the Gal4-binding domain (Gal4-BD) or Gal-4 activation domain (Gal4-AD) in pGBKT7 and pGADT7 two-hybrid vectors (Clontech) to generate pGBKT7THAP1 and pGADT7-THAP1, or downstream of the enhanced green fluorescent protein (EGFP) ORF in pEGFPC2 vector (Clontech) to generate pEGFPC2THAP1. THAP1-C1 (aa 90-213) was amplified by PCR, using pGBKT7THAP1 as template, with primers 2HMR12 (5 0 -GCGGAATTCAAAGAAGATCTTCT GGAGCCACAGGAAC-3 0 ) and 2HMR9, digested with EcoRI and BamHI, and cloned in pGBKT7 and pEGFP-C2 vectors to generate pGBKT7THAP1-C1 and pEGFPC2T HAP1-C1 expression vectors. Full-length human Par-4 was amplified by PCR from human thymus cDNA (Clontech), with primers Par-4.8 (5 0 -GCGGAATTCATGGCGACCGG TGGCTACCGGACC-3 0 ) and Par-4.5 (5 0 -GCGGGATCCC TCTACCTGGTCAGCTGACCCACAAC-3 0 ), digested with EcoRI and BamHI, and cloned in pGBKT7, pGADT7 and pEGFP-C2 vectors, to generate pGBKT7-Par-4, pGADT7-Par-4 and pEGFPC2-Par-4. pGBKT7-Par-4D (aa 1-276) and pGADT7-Par-4D were constructed by subcloning a EcoRIBglII fragment from pGADT7-Par-4 into the EcoRI and BamHI sites of pGBKT7 and pGADT7. Par-4DD (aa 250-342) was amplified by PCR, using pGBKT7-Par-4 as template, with primers Par-4.4 (5 0 -CGCGAATTCGCCATCATGGGG TTCCCTAGATATAACAGGGATGCAA-3 0 ) and Par-4.5, and cloned into the EcoRI and BamHI sites of pGBKT7 and THAP1, a link between Par-4 and PML nuclear bodies M Roussigne et al pGADT7 to obtain pGBKT7-Par-4DD and pGADT7-Par-4DD. Par-4DD (aa 250-342) was also amplified by PCR with primers Par-4.10 5 0 -GCCGGATCCGGGTTCCCTAGATA-TAACAGGGATGCAA-3 0 and Par-4.5, and cloned in frame downstream of the glutathion S-transferase ORF, into the BamHI site of the pGEX-2T prokaryotic expression vector (Amersham Pharmacia Biotech, Saclay, France). To generate pEF-mycPar-4DD eukaryotic expression vector, mycPar-4DD (aa 250-342) was amplified by PCR using pGBKT7-Par-4DD as template, with primers myc.BD7 (5 0 -GCGCTCTAGAGC-CATCATGGAGGAGCAGAAGCTGATC-3 0 ) and Par-4.9 (5 0 -CTTGCGGCCGCCTCTACCTGGTCAGCTGACCCA-CAAC-3 0 ), and cloned into the XbaI and NotI sites of the pEF-BOS expression vector (Mizushima and Nagata, 1990 ). pEGFPC2-APSK1 was generated by subcloning a EcoRIBamHI fragment from pGADT7-APSK1 (Besset et al., 2000) into the EcoRI and BamHI sites of pEGFPC2 expression vector. pEGFPC2-SUMO1 was obtained by cloning the SUMO1 coding region, amplified by PCR with primers Sumo-1 (5 0 -GAACTGCAGCTAAACTGTTGAATGACCC CCCGTTTG-3 0 ) and Sumo-2 (5 0 -GGCAGATCTTGTCT-GACCAGGAGGCAAAACCTTCAA-3 0 ) into the BglII and PstI sites of vector pEGFPC2. pcDNA.3-HA-PMLIII was constructed by subcloning a BglII-BamHI fragment from pGADT7-HA-PMLIII into the BamHI site of pcDNA3 expression vector (Invitrogen, San Diego, CA, USA). To generate pGADT7-HA-PMLIII, PMLIII ORF was amplified by PCR, using pACT2-PMLIII (a gift from Dr De The´, Paris, France) as template, with primers PML-1 (5 0 -GCGGGA TCCCTAAATTAGAAAGGGGTGGGGGTAGCC-3 0 ) and PML-2 (5 0 -GCGGAATTCATGGAGCCTGCACCCGCCC-GATC-3 0 ) and cloned into the EcoRI and BamHI sites of pGADT7. pSG5-HA-Sp100 was obtained from Dr Dejean (Institut Pasteur, Paris, France).
GST pull-down assays
GST-Par-4DD (250-342) fusion protein and control GST protein were expressed in E. coli. DH5a was purified by affinity chromatography with glutathione sepharose according to the supplier's instructions (Amersham Pharmacia Biotech). The yield of proteins used in GST pull-down assays was determined by SDS-polyarylamide gel electrophoresis (PAGE) and Coomassie blue staining analysis. In vitro-translated THAP1 and THAP1-C1 were generated with the TNT-coupled reticulocyte lysate system (Promega, Madison, WI, USA) using pGBKT7THAP1 and pGBKT7THAP1-C1 vectors as templates. A measure of 25 ml of 35 S-labelled wild-type THAP1 or THAP1-C1 was incubated with immobilized GST-Par-4 or GST proteins overnight at 41C in the following binding buffer: 10 mm NaPO4 pH 8.0, 140 mm NaCl, 3 mm MgCl2, 1 mm dithiothreitol (DTT), 0.05% NP40, and 0.2 mm phenylmethyl sulphonyl fluoride (PMSF), 1 mm Na Vanadate, 50 mm b glycerophosphate, 25 mg/ml chymotrypsine, 5 mg/ml aprotinin, 10 mg/ml leupeptin. Beads were then washed five times in 1 ml binding buffer. Bound proteins were eluted with 2 Â Laemmli SDS-PAGE sample buffer, fractionated by 10% SDS-PAGE and visualized by fluorography using Amplify (Amersham Pharmacia Biotech).
Immunofluorescence and confocal microscopy
Immunofluorescence staining of nontransfected cells and cells transfected with GFP-tagged and HA-or myc-tagged expression constructs was performed as previously described (Besset et al., 2000) . Briefly, cells were fixed for 15 min at room temperature in PBS containing 3.7% formaldehyde, and permeabilized 5 min at room temperature in PBS containing 0.1% Triton X-100. Alternatively, for Par-4 immunostaining, cells were fixed in methanol for 5 min at -201C, followed by incubation in cold acetone at -201C for 30 s. Permeabilized cells were then blocked with PBS-BSA (PBS with 1% bovine serum albumin) and incubated 2 h at room temperature with the following primary antibodies: rabbit polyclonal antibodies against human Par-4 (1/100, R-334, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or against human Daxx (1/50, M-112, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and/or mouse monoclonal antibodies anti-PML (mouse IgG1, 1/100, mAb PG-M3 from Dako, Glostrup, Denmark), anti-HA tag (mouse IgG1, 1/1000, mAb 16B12 from BabCO, Richmond, CA, USA) or anti-myc epitope (mouse IgG1, 1/200, Clontech). Cells were then washed three times in PBS-BSA and incubated for 1 h with Cy3 (red fluorescence)-conjugated goat anti-mouse or anti-rabbit IgG (1/1000, Amersham Pharmacia Biotech) or with FITC-labelled goat anti-mouse-IgG (1/40, Amersham Pharmacia Biotech) secondary antibodies, diluted in PBS-BSA. An Alexa Fluor-633 (blue fluorescence) goat anti-mouse IgG conjugate (1/100, Molecular Probes, Eugene, OR, USA) was used in triple immunofluorescence staining. After extensive washing in PBS, samples were airdried and mounted in Mowiol. Images were collected on a Leica confocal laser scanning microscope. The GFP (green), Cy3 (red) and Alexa 633 (blue) fluorescence signals were recorded sequentially for identical image fields to avoid crosstalk between the channels.
Immunohistochemistry
Tissue specimens of fresh palatine tonsils were embedded in OCT compound (TissueTek, Elkhart, IN, USA) and then snap-frozen in liquid nitrogen. Cryosections (6 mm) were airdried overnight and acetone fixed (10 min, À201C). The tissue sections were first incubated with a mixture of rabbit polyclonal antibodies against human Par-4 (1/100, R-334, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mAb Fy6 against the HEV blood vessel marker DARC (mouse IgG1, 1/30; kindly provided by R Horuk, Richmond, CA, USA) or mAb anti-PML (mouse IgG1, 1/10, mAb PG-M3 from Dako, Glostrup, Denmark), followed by a mixture of Cy3-conjugated goat anti-rabbit IgG (1/1000, Amersham Pharmacia Biotech) and Cy2-labelled goat anti-mouse-IgG (1/1000, Amersham Pharmacia Biotech) secondary antibodies, diluted in PBS-BSA. After extensive washing in PBS, samples were air-dried and mounted in Mowiol. Microscopy was performed with a Nikon Eclipse TE300 fluorescence microscope equipped with a Nikon digital camera DXM1200 (Nikon Corp., Tokyo, Japan).
Cell death assays
Mouse 3T3-TO fibroblasts were seeded on coverslips in 12-well plates at 50-80% confluency and transiently transfected with GFP or GFP-fusion protein expression vectors using Lipofectamine reagent (Life Technologies) according to the supplier's instructions or calcium phosphate method. Serum starvation of transiently transfected cells was induced 12-18 h later, by changing the medium to 0% serum, and the amount of GFP-positive apoptotic cells was assessed 24 h after induction of serum starvation. Cells were fixed in PBS containing 3.7% formaldehyde, 30 min at room temperature, and permeabilized with 0.1% Triton X-100, 0.1% THAP1, a link between Par-4 and PML nuclear bodies M Roussigne et al sodium citrate, 2 min on ice, and apoptosis was analysed by in situ terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) and/or 4,6-diamidino-2-phenylindole (DAPI) (0.2 mg/ml, 10 min at room temperature) staining of apoptotic nuclei exhibiting nuclear condensation. The TUNEL reaction was performed for 1 h at 371C using the in situ cell death detection kit, TMR red (Roche Diagnostics, Meylan, France). At least 100 cells were scored for each experimental point using a fluorescence microscope. TNFa-induced apoptosis assays were performed by incubating transiently transfected cells in complete medium containing 30 ng/ml of hTNFa (R&D, Minneapolis, MN, USA) for 24 h. Apoptosis was scored as described for serum withdrawalinduced apoptosis.
